• Topics

  • Formats

Artificial Intelligence (AI) is revolutionising the pharmaceutical commercial landscape, ushering in an era of unprecedented efficiency and innovation. Through advanced analytics and machine learning algorithms, AI is empowering pharmaceutical companies to streamline operations, enhance decision-making processes, and drive targeted marketing strategies.

By analysing vast amounts of data, AI can identify potential drug candidates faster and with greater accuracy, reducing time and costs associated with traditional methods, and bringing drugs to market faster. AI-driven predictive modelling enables companies to forecast market demand more accurately, leading to improved inventory management and resource allocation.

Furthermore, AI is transforming sales and marketing efforts by enabling personalised engagement with healthcare providers and patients. Through sophisticated algorithms, pharmaceutical companies can tailor promotional messages and educational materials to specific audiences, maximising the impact of their commercial campaigns.

Overall, the integration of AI into the pharma commercial landscape is revolutionising how drugs are discovered, developed, and marketed. As technology continues to evolve, the industry can expect further advancements that will drive efficiency, innovation, and ultimately, better patient outcomes.

Join us in this meeting where we will discuss:

  • How AI is enhancing efficiencies in commercialisation of pharmaceuticals.

  • Where are pharma teams benefiting the most from AI in the commercialisation process?

  • As AI continues to evolve, what are the emerging trends and opportunities in the pharma commercial landscape? How can pharmaceutical companies stay ahead of the curve and leverage cutting-edge AI technologies to gain a competitive advantage?

Current Participants:

  • Julie Carty - HLTH Community
  • Hima Kher - IT Sr. Director, Global External Innovation, BRISTOL-MYERS SQUIBB
  • Bartek Madej - Senior Director, Digital Health Lead International Markets and Global Lead Digital Health Business Strategy and Operations, BRISTOL MYERS SQUIBB
  • Danny Bosch - Associate Director of Business Development and Commercial, IMPERIAL COLLEGE HEALTH PARTNERS
  • Anna-Maria Heidinger - Head of Digital Innovation Hub, DAIICHI SANKYO EUROPE
  • Arun Bhatia - Commercial Strategy Lead - Digital Health, Rx+ Business Accelerator, ASTELLAS PHARMA
  • King Martins - Chief Technology Officer, PEERCAPSULE
  • Matthias Rudolph - Health Tech Solution Manager for GenAI, NOVARTIS
Available Dates

Reading this content is completely free

Enjoy Unlimited Access and Unlock
Additional Features with a Free Account

Join Now

You are attempting to log out of MyMA

Do you really want to log out?